Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Total Debt (2021 - 2024)

Standard Biotools (LAB) has disclosed Total Debt for 7 consecutive years, with $54.8 million as the latest value for Q2 2024.

  • Quarterly Total Debt rose 427.17% to $54.8 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $54.8 million through Jun 2024, up 427.17% year-over-year, with the annual reading at $8.4 million for FY2023, 2.68% up from the prior year.
  • Total Debt for Q2 2024 was $54.8 million at Standard Biotools, up from $8.4 million in the prior quarter.
  • The five-year high for Total Debt was $54.8 million in Q2 2024, with the low at $8.2 million in Q4 2022.
  • Average Total Debt over 4 years is $14.5 million, with a median of $10.2 million recorded in 2022.
  • The sharpest move saw Total Debt crashed 51.48% in 2022, then surged 427.17% in 2024.
  • Over 4 years, Total Debt stood at $16.9 million in 2021, then plummeted by 51.48% to $8.2 million in 2022, then increased by 2.68% to $8.4 million in 2023, then soared by 551.09% to $54.8 million in 2024.
  • According to Business Quant data, Total Debt over the past three periods came in at $54.8 million, $8.4 million, and $9.6 million for Q2 2024, Q4 2023, and Q3 2023 respectively.